

# Microencapsulation of Paracetamol with Polycaprolactone Coating

Elmi Sariani Hasibuan<sup>1\*</sup>, Ayus Diningsih<sup>1</sup>, Cory Linda Putri Harahap<sup>1</sup>, Anto J. Hadi<sup>2</sup>, Hafni Nur Insan<sup>2</sup>, Rini Fitriani Dongoran<sup>2</sup>, Haslinah Ahmad<sup>2</sup>, Hapiz Arlanda Sani<sup>2</sup>, Anwar Mallongi<sup>3\*</sup>

Elmi Sariani Hasibuan<sup>1\*</sup>,  
Ayus Diningsih<sup>1</sup>, Cory Linda  
Putri Harahap<sup>1</sup>, Anto J. Hadi<sup>2</sup>,  
Hafni Nur Insan<sup>2</sup>, Rini Fitriani  
Dongoran<sup>2</sup>, Haslinah Ahmad<sup>2</sup>,  
Hapiz Arlanda Sani<sup>2</sup>, Anwar  
Mallongi<sup>3</sup>

<sup>1</sup>Departemen Farmasi, Fakultas Kesehatan,  
Universitas Aupa Royhan, Padangsidempuan,  
Sumatera Utara, INDONESIA.

<sup>2</sup>Departemen Kesehatan Masyarakat,  
Fakultas Kesehatan, Universitas Aupa Royhan,  
Padangsidempuan, Sumatera Utara, INDONESIA.

<sup>3</sup>Department of Environmental Health, Faculty of  
Public Health, Hasanuddin University, Makassar,  
INDONESIA.

## Correspondence

Anwar Mallongi

Department of Environmental Health,  
Faculty of Public Health, Hasanuddin  
University, Makassar, INDONESIA.

E-mail: anwar\_envi@yahoo.com

## History

- Submission Date: 06-08-2024;
- Review completed: 19-10-2024;
- Accepted Date: 12-12-2024.

DOI : 10.5530/pj.2025.17.12

Article Available online

<http://www.phcogj.com/v17/i1>

## Copyright

© 2025 Phcogj.Com. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

## ABSTRACT

Paracetamol is widely used as a medicine for fever and pain. Paracetamol has a normal half-life in the blood of 2 hours. If paracetamol is consumed frequently it will cause stomach irritation. This research aims to cover the unpleasant taste of paracetamol by microencapsulating using a coating and changing the release of paracetamol microcapsules. In this study, the coating material used was polycaprolactone because polycaprolactone is a biodegradable coating material. The amount of coating used in this study was 1.5g, 3g and 4.5g. Paracetamol microencapsulation was carried out in evaluation tests, namely organoleptic examination and particle size. Then a characterization test was carried out, namely the surface morphology test of the paracetamol microencapsulation using the Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FTIR) method and the dissolution test. The research results showed that the concentration obtained by Formula 1 was 95.66%, Formula 2 was 97.17 and F3 was 98.81. The dissolution test results showed that the largest dissolution percentage of microcapsules in formula 1 was 97.85% at 50 minutes, formula 2 was 98.13 at 55 minutes and formula 3 was 98.91% at 60 minutes. Microencapsulation of paracetamol with polycaprolactone can cover the bitter taste and changing the release of paracetamol microcapsules into sustained release preparations.

**Keywords:** Microencapsulation, Paracetamol, Polycaprolactone.

## INTRODUCTION

Paracetamol is an analgesic drug that is used to reduce pain in the body ranging from mild to moderate. And it can also act as an antipyretic which can help reduce body temperature<sup>1</sup>. Paracetamol is used as an antipyretic and analgesic drug which is generally widely used for diseases in children and the elderly<sup>2</sup>. Paracetamol is one of the first choices used by pediatricians to treat fever and pain in accordance with national and international guidelines<sup>3</sup>. Paracetamol is an analgesic/antipyretic that is commonly known and used in combination and single formulations<sup>4</sup>.

Paracetamol (acetaminophen) is an analgesic and antipyretic drug that is sold freely and is widely used. It is usually widely used to relieve headaches and other minor aches and pains<sup>5,6</sup>. The World Health Organization (WHO) includes paracetamol on the list of essential medicines, namely drugs that are efficacious, safe and cost-effective for priority conditions<sup>7</sup>. Paracetamol has a characteristic bitter taste which is often considered to be a significant barrier to any drug administration<sup>8</sup>. Because the taste of paracetamol is bitter, some consumers avoid or are reluctant to take the medicine<sup>9</sup>. This bitter taste is one of the biggest problems in the world for the treatment of pediatric patients, causing less than optimal therapeutic value<sup>2</sup>. The therapeutic dose of paracetamol for adults is 1 g single dose or divided doses of 4x1 g every day with an administration interval of 4-6 hours. Children aged 2–12 years are usually given an individualized body weight-derived therapeutic dose of 10–15 mg/kg body weight<sup>10,11</sup>. The mechanism of action of paracetamol is not completely understood but

likely involves inhibition of cyclooxygenase-2 (COX-2). Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzyme cyclooxygenase (COX), preventing the metabolism of arachidonic acid to prostaglandin (PG) G<sub>2</sub><sup>12,13</sup>. Taste masking is an appropriate technique used to mask the bitter taste of a drug<sup>14</sup>. There are several taste masking techniques that can be used to mask taste, including microencapsulation, polymer layer formation, ion exchange, inclusion complex formation, liposomes, prodrug approaches, adsorption, various emulsion techniques, gel formation and so on<sup>12,15</sup>. One of the most effective ways to mask the unpleasant taste of drugs is to use microencapsulation techniques<sup>16</sup>.

Microencapsulation technology began to emerge in the 1950s starting with the development of dyes for capsules and inclusion in packaging<sup>17</sup>. Microencapsulation is a method used to mask undesirable flavors and aromas, this is a simple technique used to mask flavors that have relatively fewer negative impacts on consumers<sup>16,18</sup>. And currently, microencapsulation can also be defined as a series of technologies that have the aim of protecting sensitive compounds from the external environment and will also control their release. If drug release exceeds a certain time threshold, the formulation is considered to lack taste masking<sup>19</sup>. Therefore, unstable compounds are often referred to as trap cores because they are surrounded by shell or wall material. Microencapsulated isolates are most widely applied in the pharmaceutical, food, textile, agricultural, biomedical and cosmetic industries<sup>17,20</sup>.

The microencapsulation method was chosen because it has several advantages, including being able to mask the unpleasant taste of drugs, producing micro-

**Cite this article:** Hasibuan ES, Diningsih A, Harahap CLF, Hadi AJ, Insan HN, Dongoran RF, Ahmad H, et al. Pharmacogn J. 2025;17(1): 89-94.

sized drug particles, and many choices of manufacturing methods<sup>21,22</sup>. Apart from that, this method was chosen because it has several advantages, including relatively low cost, efficiency, and microcapsules having high stability<sup>23</sup>.

## METHOD

### Tools and materials

The tools used in this research are analytical scales, UV-Vis spectrophotometer, SEM, FTIR, DSC, homogenizer, measuring flask, dissolution tester, Erlenmeyer, dropper pipette and glass beaker. The materials used in this research were paracetamol, polycaprolactone, paraffin liquid, acetone, n-hexane, phosphate buffer pH 5.8, magnesium stearate, distilled water and methanol.

### Research procedure

Polycaprolactone and paracetamol were dissolved with chloroform in an Erlenmeyer flask (mass 1). Then Mg stearate was dissolved with acetone in an Erlenmeyer flask (mass 2). Mass 1 and mass 2 were put into an Erlenmeyer flask containing liquid paraffin and then stirred using a homogenizer at a speed of 250 rpm for 5 hours. The resulting microcapsules are then separated from the liquid paraffin by pouring it. The microcapsules obtained were washed using n-hexane by drying in the oven at 400 °C for 2 hours.

### Evaluation of Paracetamol Microcapsules

#### Determination of Contents

- Determination of the maximum absorption wavelength of paracetamol

Preparation of paracetamol mother liquor by dissolving 25mg paracetamol in 500 mL distilled water, resulting in a concentration of 0.05mg/mL. Solutions were made with concentrations of 2, 4, 6, 8, 10, and 12 by diluting the mother liquor. Then the absorbance was measured at a wavelength of 200-400 nm using a UV-Vis spectrophotometer.

- Creation of Calibration Curve

From the dilution results, the maximum absorption was measured and then a calibration curve was created.

- Determination of active substance levels

Paracetamol microcapsules equivalent to 120mg were weighed, then put into a 500 mL measuring flask, dissolved in 10 mL of methanol P, diluted with distilled water to the limit. Then pipette 5 mL and put into a 100 mL measuring flask, dilute with distilled water to the mark. Absorption was measured using the maximum wavelength that was obtained, the blank used was distilled water, the same treatment was carried out with each formula and the percentage of paracetamol content in the microcapsules was calculated<sup>24</sup>.

### Particle Size Distribution

The microcapsules that have been obtained are then determined for their particle size distribution using a vibration sieve. Where the sieve is graded from the largest sieve size to the smallest sieve size, namely 2000, 1000, 600, 355, 212, 150, 125 µm. Then weigh 3 grams of paracetamol microcapsules and put them in a sieve, the sieving machine will run for 10 minutes. After that, the sieve and the fractions remaining in it are weighed, and each formula<sup>25,26</sup> is repeated three times.

### Mycocapsule Morphology Scanning Electron Microscopy (SEM)

The surface morphology of the microcapsules was carried out to determine the characteristics between the coating polymer and

paracetamol<sup>27</sup>. Morphological tests were carried out using a JEOL-JSM-6510LV scanning electron microscopy (SEM) tool<sup>28</sup>.

### FTIR (Fourier Transform Infrared Spectroscopy) test

The FTIR test was carried out to determine the interaction between the coating and the active substance<sup>27</sup>. The powder sample is placed in a total reflectance (ATR) crystal device and then compressed using an axial screw<sup>29</sup>.

### Dissolution Test

In the dissolution test, 900 mL of pH 5.8 phosphate buffer solution was used as a medium. The method used is the rowing method. The steps carried out are a) Preparation of dissolution media, namely 1 L of pH 5.8 phosphate buffer mixed with 250 mL of 0.2M potassium dihydrogen phosphate then added with 18 mL of 0.2N NaOH, diluted with CO<sub>2</sub>-free water. Adjust the pH of the solution until a pH of 5.8 ± 0.05 is obtained by adding 0.2 N NaOH and increasing the volume to 1 liter. b) Put 900 mL of pH 5.8 phosphate buffer solution into the dissolution flask. c) Install the dissolution apparatus, allow the dissolution medium to reach a temperature of 37 ± 0.5 °C then insert the microcapsules into the dissolution apparatus, at a speed of 50 rpm. d) Take 5 mL samples at 5, 10, 15, 20, 25, 30 and 60 minutes. The sampling position is not less than 1 cm from the wall of the container. Each solution that has been taken is replaced again so that the amount of medium remains. e) Take 5 mL of the solution then measure the absorbance with a UV-Vis Spectrovetometer, repeat it for each formula and calculate the percentage.

## RESULTS AND DISCUSSION

The results of the examination of raw materials and coating materials have met the requirements according to the Indonesian Pharmacopoeia edition III and Indonesian Pharmacopoeia edition IV which include solubility, description, determination of levels, drying losses. The requirement for drying shrinkage is not more than 0.5%. Based on the results obtained, it was found to be 0.37%, not exceeding the provisions so that it meets the requirements. The results of determining the required levels according to the Indonesian Pharmacopoeia are 98.0%-101.0% and from the results obtained the results were 99.68, so it still meets the requirements.

### Determination of Contents

#### Determination of the maximum absorption wavelength of paracetamol

The results obtained from the paracetamol wavelength were 243.3 nm. The wavelength results show that the results obtained are not much different from the literature, namely that the wavelength of paracetamol in water is 244.2 nm<sup>30</sup>.

After obtaining the wavelength, proceed with making a paracetamol calibration curve by making a paracetamol solution with concentrations of 2, 4, 6, 8, 10 and 12 µg/mL, then measuring the absorption with the maximum wavelength obtained. The regression equation  $y = 0.0568x + 0.0423$  with  $r = 0.9997$  which shows that there is a linear relationship between the absorbance value and the concentration of the solute being analyzed. A good linear relationship has a correlation coefficient value  $r$  in linear regression analysis  $y = bx + a$ . where the linear relationship is good if the value of  $b = 0$  and the value of  $r$  is close to 1. After the calibration curve is carried out, a test is carried out to determine the active substance content of paracetamol microcapsules which is carried out according to the procedures in the Indonesian Pharmacopoeia VI edition, which is carried out using a UV spectrophotometer with medium Aquadest. The values obtained are then used to calculate the levels of paracetamol contained in paracetamol microcapsules.

The results obtained from weighing the weight of paracetamol microcapsules in formula 0 4.9324, formula 1 8.7685g, formula 2

**Table 1. Paracetamol Microcapsule Formula.**

| Material name     | Concentration |     |     |     |
|-------------------|---------------|-----|-----|-----|
|                   | F0            | F1  | F2  | F3  |
| Paracetamol (g)   | -             | 3   | 3   | 3   |
| PCL (g)           | 1.5           | 1.5 | 3   | 4.5 |
| Chloroform (mL)   | 10            | 10  | 15  | 20  |
| Mg Stearate (g)   | 0.5           | 0.5 | 1   | 1.5 |
| Acetone (mL)      | 5             | 5   | 8   | 11  |
| Paraffin Liq (mL) | 100           | 100 | 100 | 100 |

**Table 2. Determination of Microcapsule Concentrations.**

| Microcapsules | Heavy Microcapsules | Acquisition Return Microcapsules | Acquisition Return Substance Active |
|---------------|---------------------|----------------------------------|-------------------------------------|
| F0            | 4.9324              | 98,365                           | -                                   |
| F1            | 8.7685              | 95.6632                          | 68.4537±2.31                        |
| F2            | 11.0142             | 97.1782                          | 61.1492 ± 2.17                      |
| F3            | 13.2916             | 98.8197                          | 56.3657±1.26                        |

**Table 3. Particle Size Distribution Measurement Results.**

| Sieve size (µm) | Fraction of sieve retained (%) |           |           |
|-----------------|--------------------------------|-----------|-----------|
|                 | Formula 1                      | Formula 2 | Formula 3 |
| 125 – 150       | 1.52                           | 0.38      | 0.67      |
| 150 – 212       | 0.89                           | 3.04      | 1.03      |
| 212 – 355       | 4.15                           | 3.21      | 3.35      |
| 355 – 425       | 5.09                           | 2.65      | 5.63      |
| 425 – 600       | 3.61                           | 4.54      | 11.28     |
| 600 – 1000      | 33.11                          | 35.76     | 19.34     |
| 1000 – 2000     | 25.47                          | 31.64     | 27.48     |
| 0 – 2000        | 25.42                          | 18.78     | 30.45     |

11.0142, formula 3 13.2916 and for the recovery of paracetamol microcapsules in each formula were 98.365, 95.6632, 97.1782, 98.8197. From the test results for determining the levels in paracetamol microcapsules from the three formulas with each comparison, it can be seen that the greater the coating ratio, the smaller the active substance obtained. Where F1 contains more active substances than F2 and F3. F1 68.4537, F2 61.1492, F3 56.3657, from the results obtained it is clear that F1 has the highest active substance content due to the effect of size on the microcapsules where the smaller the particle diameter, the greater the ability to absorb drugs<sup>25</sup> while F3 has the lowest active substance content because the thicker the coating used, the less drug content it contains<sup>25,31</sup>. Results can be seen in table 2.

From the results of examining the particle size distribution using a multilevel sieve, it was found that the particle size of paracetamol microcapsules with polycaprolactone coating was between 125-2000 µm. The sizes obtained have differences in particle size distribution which is greatly influenced by the amount of coating used as a layer to form the microcapsule walls. The particle size obtained meets the requirements for microcapsules, namely 5-5000µm<sup>25,32</sup>. Results can be seen in table 3.

**Mycapsule Morphology Scanning Electron Microscopy (SEM)**


Microscopic evaluation of microcapsules was carried out using SEM tests with 500x magnification. The aim of this test was to see the morphology of each paracetamol microcapsules formula. The results of the paracetamol microcapsule test using SEM can be seen in Figure 2.

The results of observing the morphology of paracetamol with polycaprolactone at a magnification of 500 times using SEM showed that the surface of formula 3 was rougher than formulas 1 and 2. From the results it could be concluded that as the concentration of the coating used increased, the resulting surface became rougher.


**FTIR ( Fourier Transform Infrared Spectroscopy ) test**

The FTIR test was carried out to determine the interaction between paracetamol and polycaprolactone. The interaction between paracetamol and polycaprolactone is indicated by the presence of a new peak or a shifted peak<sup>29</sup>.


The FTIR spectrum results of paracetamol microcapsules formulas 1, 2 and 3 in table 4 show that the peak spectrum produced is not much different from the IR spectrum of the raw material, the three formulas have some of the same spectrum results as the spectrum of paracetamol and polycaprolactone. From the results of the wavelength numbers in formulas 1, 2 and 3, there is no visible shift in the wave numbers. This shows that there is no interaction between the active substance and the polymer used as a coating so that it does not produce new functional groups or new bonds.



**Figure 1. Maximum Absorption Wavelength of Paracetamol (λ = 244.2 nm).**



**Figure 2. SEM micrograph.**



**Figure 3. Dissolution Curve of Paracetamol Microcapsules for Each Formula.**

**Table 4. Wave Numbers of Paracetamol, Polycaprolactone, Formula 1, Formula 2 and Formula 3.**

| Functional groups | Paracetamol BPF1 | Paracetamol | Polycaprolactone | F1      | F2      | F3      |
|-------------------|------------------|-------------|------------------|---------|---------|---------|
| NH                | 3321.42          | 3323.37     | -                | 3323.37 | 3323.37 | 3323.37 |
| C=O               | 1732.08          | 1878.67     | 1722.43          | 1722.43 | 1722.43 | 1722.43 |
| OH                | 3161.33          | 3151.36     | -                | 3143.24 | 3143.24 | 3143.24 |
| C.N               | 1327.03          | 1327.03     | 1363.67          | 1363.38 | 1363.38 | 1363.38 |
| C=C Aromatic      | 1651.07          | 1651.06     | -                | 1651.05 | 1651.05 | 1651.05 |
| CH                | 1435.04          | 1445.06     | 1417.68          | 1435.06 | 1435.06 | 1435.06 |
| CH <sub>2</sub>   | 2929.87          | 2867.76     | 2864.29          | 2948.67 | 2948.67 | 2948.67 |
| CO                | 968.27           | 968.27      | 960.55           | 967.21  | 967.21  | 967.21  |

**Table 5. Percent of Dissolved Substances.**

| Time | % dissolved        |       |       |       |
|------|--------------------|-------|-------|-------|
|      | Powder Paracetamol | F 1   | F 2   | F 3   |
| 5    | 21.58              | 41.88 | 39.08 | 37.16 |
| 10   | 39.67              | 47.16 | 45.97 | 41.77 |
| 15   | 56.54              | 52.87 | 50.88 | 46.75 |
| 20   | 64.53              | 59.06 | 56.43 | 53.43 |
| 25   | 81.85              | 63.45 | 61.81 | 60.79 |
| 30   | 98.32              | 69.95 | 67.32 | 65.81 |
| 35   |                    | 76.83 | 74.76 | 71.08 |
| 40   |                    | 82.49 | 80.78 | 78.82 |
| 45   |                    | 89.91 | 87.05 | 84.81 |
| 50   |                    | 97.85 | 93.28 | 92.75 |
| 55   |                    |       | 98.13 | 96.14 |
| 60   |                    |       |       | 98.91 |

**Table 6. Kinetic Model of Active Substance Release from Microcapsules.**

| Kinetic Model   | R <sup>2</sup> |        |        |
|-----------------|----------------|--------|--------|
|                 | F1             | F2     | F3     |
| Order 0         | 0.9167         | 0.8992 | 0.9657 |
| Order 1         | 0.9364         | 0.9122 | 0.9477 |
| Higuchi         | 0.9192         | 0.9132 | 0.9746 |
| Kosmeyer-Peppas | 0.8828         | 0.8623 | 0.9481 |
| Langenburcher   | 0.8776         | 0.8769 | 0.9582 |

## Dissolution Test

The dissolution test is carried out to measure and determine the amount of active substance dissolved in a known volume of liquid media at a certain time using a tool so as to determine the speed of release of the drug from the solid dosage form. The dissolution test results can be seen in table 5.

From the results of the dissolution profile test, it can be seen the difference in propyl release between paracetamol powder and paracetamol microcapsules for 60 minutes. The percentage obtained from dissolvable substances in paracetamol powder at 30 minutes was 98.32%. The percentage of dissolvable substances in paracetamol microcapsules for formula 1 at 50 minutes was 97.85%, formula 2 at 55 minutes was 98.13% and formula 3 at 60 minutes was 98.91%. From the results of the dissolution test it was found that the release of active substances from microcapsules was not the same as the release of active substances in powder form which did not undergo a microencapsulation process, for formula 1 the release of active substances was faster than formulas 2 and 3 because in the microencapsulation process each formulation had a ratio of each polymer. where formulation 1 is lower than formulations 2 and 3 so that the release of the active substance takes longer in formulation 3<sup>33,34-41</sup>. From the results of the dissolution test it can be concluded that making paracetamol into microcapsules affects the release of the drug more slowly.

The results of determining the kinetic model for the release of paracetamol microcapsules have been carried out and are based on zero order, 1st order, Higuchi, Korsmeyer-Peppas and Langerburch equations. From the results of the five kinetic models, the relationship coefficient obtained from formulas 1, 2 and 3 which is closest to 0.999 is the 1st Order equation where the amount of drug released is proportional to the square root of the time to reach the maximum concentration, not depending on the dose but on the absorption rate constant<sup>34, 35</sup>.

## CONCLUSION

From the research results, it was concluded that paracetamol can be made into microcapsules. Polycaprolactone used as a slow-release polymer can have an effect on paracetamol microcapsules and can slow down the process of releasing the active substance which can be seen from the dissolution results.

## REFERENCES

1. Shams T, Parhizkar M, Illangakoon UE, Orlu M, Edirisinghe M. Core/shell microencapsulation of indomethacin/paracetamol by co-axial electrohydrodynamic atomization. Mater Des [Internet]. 2017 Dec;136:204–13. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264127517309048>

2. Almurisi SH, Doolaanea AA, Akkawi ME, Chatterjee B, Sarker MZI. Taste masking of paracetamol encapsulated in chitosan-coated alginate beads. *J Drug Deliv Sci Technol* [Internet]. 2020 Apr;56:101520. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1773224719315771>
3. Conaghan PG, Arden N, Avouac B, Migliore A, Rizzoli R. Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? *Drugs and Aging* [Internet]. 2019;36(s1):7–14. Available from: <https://doi.org/10.1007/s40266-019-00658-9>
4. Partheniadis I, Nikolakakis I, Zacharis CK, Kachrimanis K, Al-Zoubi N. Co-Spray Drying of Paracetamol and Propylphenazone with Polymeric Binders for Enabling Compaction and Stability Improvement in a Combination Tablet. *Pharmaceutics* [Internet]. 2021 Aug 14;13(8):1259. Available from: <https://www.mdpi.com/1999-4923/13/8/1259>
5. Singh S, Bajpai YK, Parveen G. Formulation and Evaluation of Albumin Microspheres of Paracetamol. *J Res Appl Sci Biotechnol* [Internet]. 2022 Dec 12;1(5):125–32. Available from: <https://jrasb.com/index.php/jrasb/article/view/103>
6. Kamilya T, Majumder A, Saidulu D, Tripathy S, Gupta AK. Optimization of a continuous hybrid moving bed biofilm reactor and constructed wetland system for the treatment of paracetamol-spiked domestic wastewater. *Chem Eng J* [Internet]. 2023 Nov;147139. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1385894723058709>
7. Abdel Shaheed C, Ferreira GE, Dmitritchenko A, McLachlan AJ, Day RO, Saragiotto B, et al. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. *Med J Aust* [Internet]. 2021 Apr 30;214(7):324–31. Available from: <https://onlinelibrary.wiley.com/doi/10.5694/mja2.50992>
8. Almurisi SH, Doolaanea AA, Akkawi ME, Chatterjee B, Ahmed Saeed Aljapairai K, Islam Sarker MZ. Formulation development of paracetamol instant jelly for pediatric use. *Drug Dev Ind Pharm* [Internet]. 2020 Aug 2;46(8):1373–83. Available from: <https://www.tandfonline.com/doi/full/10.1080/03639045.2020.1791165>
9. de Oliveira GGG, Feitosa A, Loureiro K, Fernandes AR, Souto EB, Severino P. Compatibility study of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in physical mixtures. *Saudi Pharm J* [Internet]. 2017 Jan;25(1):99–103. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1319016416300299>
10. Spildrejorde M, Samara A, Sharma A, Leithaug M, Falck M, Modafferi S, et al. Multi-omics approach reveals dysregulated genes during hESCs neuronal differentiation exposure to paracetamol. *iScience* [Internet]. 2023 Oct;26(10):107755. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2589004223018321>
11. Esh CJ, Mauger AR, Palfreeman RA, Al-Janubi H, Taylor L. Acetaminophen (Paracetamol): Use beyond Pain Management and Dose Variability. *Front Physiol* [Internet]. 2017 Dec 22;8. Available from: <http://journal.frontiersin.org/article/10.3389/fphys.2017.01092/full>
12. Yousefi M, Khanniri E, Shadnoush M, Khorshidian N, Mortazavian AM. Development, characterization and in vitro antioxidant activity of chitosan-coated alginate microcapsules entrapping *Viola odorata* Linn. extract. *Int J Biol Macromol* [Internet]. 2020 Nov;163:44–54. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0141813020337041>
13. Grenha A, Guerreiro F, Lourenço JP, Lopes JA, Câmara-Martos F. Microencapsulation of selenium by spray-drying as a tool to improve bioaccessibility in food matrices. *Food Chem* [Internet]. 2023 Feb;402:134463. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0308814622024256>
14. Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years. *JAMA Netw Open* [Internet]. 2020 Oct 30;3(10):e2022398. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772373>
15. Busch VM, Pereyra-Gonzalez A, Šegatin N, Santagapita PR, Poklar Ulrih N, Buera MP. Propolis encapsulation by spray drying: Characterization and stability. *LWT* [Internet]. 2017 Jan;75:227–35. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0023643816305527>
16. Khor CM, Ng WK, Kanaujia P, Chan KP, Dong Y. Hot-melt extrusion microencapsulation of quercetin for taste-masking. *J Microencapsul* [Internet]. 2017 Jan 2;34(1):29–37. Available from: <https://www.tandfonline.com/doi/full/10.1080/02652048.2017.1280095>
17. Perez-Palacios T, Ruiz-Carrascal J, Solomando JC, De-la-Haba F, Pajuelo A, Antequera T. Recent Developments in the Microencapsulation of Fish Oil and Natural Extracts: Procedure, Quality Evaluation and Food Enrichment. *Foods* [Internet]. 2022 Oct 20;11(20):3291. Available from: <https://www.mdpi.com/2304-8158/11/20/3291>
18. Pauletto PS, Lütke SF, Dotto GL, Salau NPG. Exploring the simultaneous mass transport of nimesulide and paracetamol adsorption on activated carbon: A PVSDM approach. *Sep Purif Technol* [Internet]. 2024 Jan;329:125148. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1383586623020567>
19. Keeley A, Teo M, Ali Z, Frost J, Ghimire M, Rajabi-Siahboomi A, et al. In Vitro Dissolution Model Can Predict the in Vivo Taste Masking Performance of Coated Multiparticulates. *Mol Pharm* [Internet]. 2019 May 6;16(5):2095–105. Available from: <https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.9b00060>
20. Chen H, Xiong M, Bai T, Chen D, Zhang Q, Lin D, et al. Comparative study on the structure, physicochemical, and functional properties of dietary fiber extracts from quinoa and wheat. *Via* [Internet]. 2021;149(May):111816. Available from: <https://doi.org/10.1016/j.lwt.2021.111816>
21. Singh M, Menra JSD, Soni M, Prasad. D.N. Microencapsulation And Its Various Aspects: A Review. *Int J Adv Res* [Internet]. 2016 May 31;4(6):2094–108. Available from: <http://www.journalijar.com/article/10339/microencapsulation-and-its-various-aspects-a-review-/>
22. Yuan L, Feng W, Zhang Z, Peng Y, Xiao Y, Chen J. Effect of potato starch-based antibacterial composite films with thyme oil microemulsion or microcapsule on shelf life of chilled meat. *LWT* [Internet]. 2021 Mar;139:110462. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S002364382031450X>
23. Mohammed NK, Tan CP, Manap YA, Muhialdin BJ, Hussin ASM. Spray Drying for the Encapsulation of Oils—A Review. *Molecules* [Internet]. 2020 Aug 26;25(17):3873. Available from: <https://www.mdpi.com/1420-3049/25/17/3873>
24. Bayryamov SG. Microencapsulation of Natural Oils By a Coacervation Technique Using Gelatin As Shell Material. *J Chem Technol Metall*. 2020;55(6):1985–9.
25. Harsep Rosi D. Microencapsulation of Paracetamol Using Eudragit L100 as a Coating. 2022;92–100.
26. Bolaños-Méndez D, Alvarez-Paguay J, Fernández L, Saavedra-Alulema PF, Veloz-Romero MS, Espinoza-Montero PJ. An inexpensive paracetamol sensor based on an acid-activated carbon fiber microelectrode. *Chemosphere* [Internet]. 2023 Nov;140586. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0045653523028564>
27. Hasibuan ES, Djamaan A, Suardi M. Manufacturing and Characterization of Urea Tablets Using the Direct Compression Method. *J Educ Dev* [Internet]. 2023 Jan 11;11(1):511–6. Available from: <https://journal.ipts.ac.id/index.php/ED/article/view/4525>
28. Liu W, Price S, Bennett G, Maxwell TMR, Zhao C, Walker G, et al. A landscape review of controlled release urea products: Patent objectives, formulation and technology. *J Control Release* [Internet]. 2022 Aug;348:612–30. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0168365922003388>

29. Sulistyani M, Huda N. Comparison of Transmission and Reflectance Methods in Polystyrene Measurements Using Fourier Transform Infrared Spectroscopy Instrumentation. *Indonesian J Chem Sci*. 2018;7(2):195–8.
30. RI K. Indonesian Pharmacopoeia VI edition. Ministry of Health of the Republic of Indonesia. 2020.
31. Peng X, Umer M, Pervez MN, Hasan KMF, Habib MA, Islam MS, et al. Biopolymers-based microencapsulation technology for sustainable textiles development: A short review. *Case Stud Chem Environ Eng* [Internet]. 2023 Jun;7:100349. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2666016423000543>
32. Laureanti EJG, Paiva TS, de Matos Jorge LM, Jorge RMM. Microencapsulation of bioactive compound extracts using maltodextrin and gum arabic by spray and freeze-drying techniques. *Int J Biol Macromol* [Internet]. 2023 Dec;253:126969. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0141813023038667>
33. Diaz Vergara LI, Arata Badano J, Aminahuel CA, Vanden Braber NL, Rossi YE, Pereyra CM, et al. Chitosan-glucose derivative as effective wall material for probiotic yeasts microencapsulation. *Int J Biol Macromol* [Internet]. 2023 Dec;253:127167. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0141813023040643>
34. Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: A Review of Guideline Recommendations. *J Clin Med* [Internet]. 2021 Jul 31;10(15):3420. Available from: <https://www.mdpi.com/2077-0383/10/15/3420>
35. Muhith A, Winarti E, Perdana SSI, Haryuni S, Rahayu KIN, Mallongi A. Internal Locus of Control as a Driving Factor of Early Detection Behavior of Cervical Cancer by Inspection Visual of Acetic Acid Method. *Open Access Maced J Med Sci* [Internet]. 2020 Apr. 20 [cited 2022 Nov. 10];8(E):113-6.
36. Hasmi and Mallongi, A. 2016. Health Risk Analysis of Lead Exposure from Fish Consumption among Communities along Youtefa Gulf, Jayapura. *Pakistan Journal of Nutrition*, 15. 929-935.
37. Posmaningsih, S., Aryasih, S. K. M., Made, I. G. A., Choirul Hadi, M., Marwati, S. P., & Mallongi, A. (2018). The influence of media booklet in behavior change of waste management in elementary school students, South Denpasar, Bali. *Indian Journal of Public Health Research & Development*, 9(8), 1506-1511.
38. Anwar Mallongi, Anwar Daud, Hasanuddin Ishak, Ruslan La Ane, Agus Bintara Birawida, Erniwati Ibrahim, Makmur Selomo and Stang Abdul Rahman. Clean water treatment technology with an up-flow slow sand filtration system from a well water source in the tallo district of makassar. 2016. *Journal of Environmental Science and Technology* 10(1):44-48. DOI: 10.3923/jest.2017.44.48
39. Mallongi, A., & Ernyasih, E. (2022). Assessment of low-cost mercury absorbent to minimize the mercury environmental and health effects in Makassar coastal areas. *Journal of Advanced Pharmacy Education and Research*, 12(4), 32-38. <https://doi.org/10.51847/XfBn7cm7wH>
40. Mallongi, A., Stang., Ernyasih., Palutturi, S., Rauf, A. U., Astuti, R. D. P., Birawida, A. B. (2023). Calculating Health and Ecological Risks of Pm2.5, and Lead Pollutants Exposure Among Communities Due to Cement Plant Emission, Maros Indonesia 2023. *Journal Of Law And Sustainable Development.*, Miami, v.11, n. 9, pages: 01-19, e01048
41. Zhang Q, Fan W, Shi Y, Tu Z, Hu Y, Zhang J. Interaction between soy protein isolate/whey protein isolate and sucrose ester during microencapsulation: Multi-spectroscopy and molecular docking. *LWT* [Internet]. 2023 Oct;188:115363. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0023643823009428>

**Cite this article:** Hasibuan ES, Diningsih A, Harahap CLF, Hadi AJ, Insan HN, Dongoran RF, Ahmad H, et al. *Pharmacogn J*. 2025;17(1): 89-94.